- Home
- GMAB vs TAP Comparison
GMAB vs TAP Comparison
Compare GMAB & TAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TAP
- Stock Information
- Founded
- GMAB 1999
- TAP 1873
- Country
- GMAB Denmark
- TAP United States
- Employees
- GMAB N/A
- TAP N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TAP Beverages (Production/Distribution)
- Sector
- GMAB Health Care
- TAP Consumer Staples
- Exchange
- GMAB Nasdaq
- TAP Nasdaq
- Market Cap
- GMAB 15.0B
- TAP 12.6B
- IPO Year
- GMAB N/A
- TAP N/A
- Fundamental
- Price
- GMAB $21.80
- TAP $55.74
- Analyst Decision
- GMAB Buy
- TAP Hold
- Analyst Count
- GMAB 8
- TAP 14
- Target Price
- GMAB $43.00
- TAP $61.79
- AVG Volume (30 Days)
- GMAB 1.1M
- TAP 1.7M
- Earning Date
- GMAB 02-12-2025
- TAP 02-13-2025
- Dividend Yield
- GMAB N/A
- TAP 3.17%
- EPS Growth
- GMAB 14.35
- TAP 275.92
- EPS
- GMAB 10.80
- TAP 4.42
- Revenue
- GMAB $2,967,926,227.00
- TAP $11,682,200,000.00
- Revenue This Year
- GMAB $32.03
- TAP $0.08
- Revenue Next Year
- GMAB $16.97
- TAP N/A
- P/E Ratio
- GMAB $19.02
- TAP $12.61
- Revenue Growth
- GMAB 17.75
- TAP 1.23
- 52 Week Low
- GMAB $19.85
- TAP $49.19
- 52 Week High
- GMAB $31.88
- TAP $69.18
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- TAP 44.59
- Support Level
- GMAB $19.89
- TAP $54.02
- Resistance Level
- GMAB $21.26
- TAP $55.11
- Average True Range (ATR)
- GMAB 0.42
- TAP 1.30
- MACD
- GMAB 0.02
- TAP 0.04
- Stochastic Oscillator
- GMAB 80.08
- TAP 63.22
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About TAP Molson Coors Beverage Company Class B
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.